These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1675550

  • 1. Clinical pharmacology of ibopamine.
    Itoh H.
    Am J Med; 1991 May 29; 90(5B):36S-42S. PubMed ID: 1675550
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
    Marchetti GV.
    Cardiology; 1990 May 29; 77 Suppl 5():22-9. PubMed ID: 1980631
    [Abstract] [Full Text] [Related]

  • 3. [Ibopamine--pharmacologic principles].
    Borchard U.
    Z Kardiol; 1991 May 29; 80 Suppl 8():63-6. PubMed ID: 1686693
    [Abstract] [Full Text] [Related]

  • 4. Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.
    Kopia GA, Ohlstein EH, Ruffolo RR.
    J Pharmacol Exp Ther; 1988 Aug 29; 246(2):434-40. PubMed ID: 3404441
    [Abstract] [Full Text] [Related]

  • 5. Acute haemodynamic effects of ibopamine and dopamine on isovolumic relaxation.
    Bernardi L, Perlini S, Soffiantino F, Farilla C, Calciati A, Soldá PL, Paro M, Merlo L, Marchetti G, Finardi G.
    Eur J Pharmacol; 1989 May 30; 164(3):415-24. PubMed ID: 2767116
    [Abstract] [Full Text] [Related]

  • 6. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
    López-Sendón J.
    Am J Med; 1991 May 29; 90(5B):43S-49S. PubMed ID: 1675551
    [Abstract] [Full Text] [Related]

  • 7. Renal and neurohumoral effects of ibopamine and metoclopramide in normal man.
    Girbes AR, van Veldhuisen DJ, Smit AJ, Drent-Bremer A, Meijer S, Reitsma WD.
    Br J Clin Pharmacol; 1991 Jun 29; 31(6):701-4. PubMed ID: 1678273
    [Abstract] [Full Text] [Related]

  • 8. [Mechanism of action of ibopamine: pharmacological effects of epinine and other metabolites].
    Ferrini R, Merlo L, Miragoli G.
    Cardiologia; 1988 Jan 29; 33(1):49-53. PubMed ID: 2835159
    [No Abstract] [Full Text] [Related]

  • 9. Assessment of the cardiohemodynamic effects of ibopamine, an orally-active dopamine analogue, in the anesthetized open-chest guinea pig and the isolated guinea pig atria.
    Matsui K, Imai S.
    Jpn J Pharmacol; 1986 Oct 29; 42(2):217-27. PubMed ID: 3795623
    [Abstract] [Full Text] [Related]

  • 10. Coronary vascular activity of the novel inotropic pro-drug ibopamine and the de-esterified active form epinine.
    Ohlstein EH, Kopia GA, Ruffolo RR.
    Arzneimittelforschung; 1988 Dec 29; 38(12):1790-2. PubMed ID: 3245851
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamine.
    Nichols AJ, Shebuski RJ, Ruffolo RR.
    Eur J Pharmacol; 1987 Sep 23; 141(3):515-8. PubMed ID: 3666046
    [Abstract] [Full Text] [Related]

  • 12. Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Henwood JM, Todd PA.
    Drugs; 1988 Jul 23; 36(1):11-31. PubMed ID: 3063492
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ, Smith JM, Shebuski RJ, Ruffolo RR.
    J Pharmacol Exp Ther; 1987 Aug 23; 242(2):573-8. PubMed ID: 2886644
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics of ibopamine on different diseases and conditions.
    Ventresca GP, Lodola E.
    Arzneimittelforschung; 1988 Aug 23; 38(8):1175-80. PubMed ID: 2904270
    [Abstract] [Full Text] [Related]

  • 15. Effect of dopamine, ibopamine, and epinine on alpha- and beta-adrenoceptors in canine pulmonary circulation.
    Shebuski RJ, Smith JM, Ruffolo R.
    Fundam Clin Pharmacol; 1989 Aug 23; 3(3):211-21. PubMed ID: 2548941
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular and renal action of dopaminergic prodrugs.
    Casagrande C, Merlo L, Ferrini R, Miragoli G, Semeraro C.
    J Cardiovasc Pharmacol; 1989 Aug 23; 14 Suppl 8():S40-59. PubMed ID: 2483441
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure.
    López-Sendón J.
    Cardiology; 1990 Aug 23; 77 Suppl 5():9-21. PubMed ID: 1980634
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the positive inotropic effect of ibopamine in the blood-perfused canine papillary muscle.
    Kawahara K, Inui J.
    J Cardiovasc Pharmacol; 1985 Aug 23; 7(2):316-20. PubMed ID: 2581086
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.
    Nichols AJ, Ruffolo RR.
    J Pharmacol Exp Ther; 1987 Aug 23; 242(2):455-63. PubMed ID: 3039117
    [Abstract] [Full Text] [Related]

  • 20. Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure.
    Musacci GF, Ansani L, Toselli T, Aggio S, Baracca E, Longhini C.
    Arzneimittelforschung; 1986 Feb 23; 36(2A):380-2. PubMed ID: 3707654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.